Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028840 | 1.00 | LMNA (0.49) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL1722127 | 0.85 | KDM4E (0.55) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL4659964 | 0.85 | KDM4E (0.55) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL1722125 | 0.85 | KDM4E (0.55) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL30379656 | 0.81 | LMNA (0.48) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL20603125 | 0.81 | LMNA (0.48) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL4661444 | 0.77 | LMNA (0.61) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL4661446 | 0.77 | LMNA (0.61) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL14689450 | 0.74 | EGFR (0.49) | LMNAKDM4EALDH1A1CISD1SLC16A3 | |
| SCHEMBL2459356 | 0.74 | EGFR (0.49) | LMNAKDM4EALDH1A1CISD1SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| CN-101801980-A | tricyclic heterocyclic derivatives | ORGANON NV | 2010-08-11 | — | — | CN | disclosed |
| EP-2203454-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. Organon (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | LMNA 4564/4885KDM4E 2053/4885ALDH1A1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.